PortalPublikationenHBsAg level at time of liver transplantation determines HBsA...

HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.

Standard

HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. / Rosenau, Jens; Kreutz, Therese; Kujawa, Matthias; Bahr, Matthias J; Rifai, Kinan; Hooman, Nazanin; Finger, Andrea; Michel, Gerd; Nashan, Björn; Kuse, Ernst R; Klempnauer, Jürgen; Tillmann, Hans L; Manns, Michael P.

in: J HEPATOL, Jahrgang 46, Nr. 4, 4, 2007, S. 635-644.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rosenau, J, Kreutz, T, Kujawa, M, Bahr, MJ, Rifai, K, Hooman, N, Finger, A, Michel, G, Nashan, B, Kuse, ER, Klempnauer, J, Tillmann, HL & Manns, MP 2007, 'HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.', J HEPATOL, Jg. 46, Nr. 4, 4, S. 635-644. <http://www.ncbi.nlm.nih.gov/pubmed/17316869?dopt=Citation>

APA

Rosenau, J., Kreutz, T., Kujawa, M., Bahr, M. J., Rifai, K., Hooman, N., Finger, A., Michel, G., Nashan, B., Kuse, E. R., Klempnauer, J., Tillmann, H. L., & Manns, M. P. (2007). HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J HEPATOL, 46(4), 635-644. [4]. http://www.ncbi.nlm.nih.gov/pubmed/17316869?dopt=Citation

Vancouver

Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J HEPATOL. 2007;46(4):635-644. 4.

Bibtex

@article{0bf04e5c4fa14fcdac0fd897d6391d57,
title = "HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.",
abstract = "BACKGROUND/AIMS: Administration of hepatitis B immunoglobulin (HBIG) initially after liver transplantation of hepatitis B patients is considered important to prevent reinfection reliably. However, dosing schedules differ considerably between centers. We measured HBsAg, anti-HBs and HBV DNA kinetics to create a rational basis for dosing schemes. METHODS: Thirteen patients (group A) received 10,000 IU HBIG in the anhepatic phase followed by 10,000 IU daily until HBsAg became negative, whereas five patients (group B) received 20,000 IU followed by 5000 IU every 30 min. RESULTS: HBsAg levels at time of transplantation ranged from 0.12 to 12,990 IU/ml. Correlations between initial HBsAg and HBIG required to decrease HBsAg below 1 IU/ml were high in groups A and B (r=0.97, p",
author = "Jens Rosenau and Therese Kreutz and Matthias Kujawa and Bahr, {Matthias J} and Kinan Rifai and Nazanin Hooman and Andrea Finger and Gerd Michel and Bj{\"o}rn Nashan and Kuse, {Ernst R} and J{\"u}rgen Klempnauer and Tillmann, {Hans L} and Manns, {Michael P}",
year = "2007",
language = "Deutsch",
volume = "46",
pages = "635--644",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.

AU - Rosenau, Jens

AU - Kreutz, Therese

AU - Kujawa, Matthias

AU - Bahr, Matthias J

AU - Rifai, Kinan

AU - Hooman, Nazanin

AU - Finger, Andrea

AU - Michel, Gerd

AU - Nashan, Björn

AU - Kuse, Ernst R

AU - Klempnauer, Jürgen

AU - Tillmann, Hans L

AU - Manns, Michael P

PY - 2007

Y1 - 2007

N2 - BACKGROUND/AIMS: Administration of hepatitis B immunoglobulin (HBIG) initially after liver transplantation of hepatitis B patients is considered important to prevent reinfection reliably. However, dosing schedules differ considerably between centers. We measured HBsAg, anti-HBs and HBV DNA kinetics to create a rational basis for dosing schemes. METHODS: Thirteen patients (group A) received 10,000 IU HBIG in the anhepatic phase followed by 10,000 IU daily until HBsAg became negative, whereas five patients (group B) received 20,000 IU followed by 5000 IU every 30 min. RESULTS: HBsAg levels at time of transplantation ranged from 0.12 to 12,990 IU/ml. Correlations between initial HBsAg and HBIG required to decrease HBsAg below 1 IU/ml were high in groups A and B (r=0.97, p

AB - BACKGROUND/AIMS: Administration of hepatitis B immunoglobulin (HBIG) initially after liver transplantation of hepatitis B patients is considered important to prevent reinfection reliably. However, dosing schedules differ considerably between centers. We measured HBsAg, anti-HBs and HBV DNA kinetics to create a rational basis for dosing schemes. METHODS: Thirteen patients (group A) received 10,000 IU HBIG in the anhepatic phase followed by 10,000 IU daily until HBsAg became negative, whereas five patients (group B) received 20,000 IU followed by 5000 IU every 30 min. RESULTS: HBsAg levels at time of transplantation ranged from 0.12 to 12,990 IU/ml. Correlations between initial HBsAg and HBIG required to decrease HBsAg below 1 IU/ml were high in groups A and B (r=0.97, p

M3 - SCORING: Zeitschriftenaufsatz

VL - 46

SP - 635

EP - 644

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 4

M1 - 4

ER -